GS-3583 + zimberelimab + cisplatin + carboplatin + 5-fluorouracil

GS-3583 + zimberelimab + cisplatin + carboplatin + 5-fluorouracil is an investigational combination regimen containing five agents: GS-3583 (a proprietary investigational drug, possibly a novel immunotherapeutic or checkpoint inhibitor, for which published mechanism or developer information is not available), **zimberelimab** (an anti-PD-1 monoclonal antibody immune checkpoint inhibitor), **cisplatin** (a platinum-based antineoplastic that forms DNA crosslinks and inhibits DNA synthesis and function), **carboplatin** (a less nephrotoxic platinum-based chemotherapeutic with a similar mechanism to cisplatin), and **5-fluorouracil** (5-FU, a pyrimidine analog antimetabolite that inhibits thymidylate synthase, impairing DNA synthesis). This combination leverages immunotherapy (zimberelimab, possibly GS-3583) and multiple chemotherapy agents utilized for synergistic cytotoxicity and immune activation, typically in cancers such as locally advanced or metastatic squamous cell carcinomas of the head, neck, or esophagus[2][3]. No regulatory approval or wide clinical use is currently established for this specific five-drug combination.

Brand names

none

Other names

zimberelimab + cisplatin + carboplatin + 5-fluorouracil